Tengattini Sara, Rubes Davide, Serra Massimo, Piubelli Luciano, Pollegioni Loredano, Calleri Enrica, Bavaro Teodora, Massolini Gabriella, Terreni Marco, Temporini Caterina
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.
Department of Biotechnology and Life Sciences, University of Insubria, Via Dunant 3, 21100 Varese, Italy.
Pharmaceutics. 2023 Apr 23;15(5):1321. doi: 10.3390/pharmaceutics15051321.
Conjugation via disuccinimidyl homobifunctional linkers is reported in the literature as a convenient approach for the synthesis of glycoconjugate vaccines. However, the high tendency for hydrolysis of disuccinimidyl linkers hampers their extensive purification, which unavoidably results in side-reactions and non-pure glycoconjugates. In this paper, conjugation of 3-aminopropyl saccharides via disuccinimidyl glutarate (DSG) was exploited for the synthesis of glycoconjugates. A model protein, ribonuclease A (RNase A), was first considered to set up the conjugation strategy with mono- to tri- mannose saccharides. Through a detailed characterization of synthetized glycoconjugates, purification protocols and conjugation conditions have been revised and optimized with a dual aim: ensure high sugar-loading and avoid the presence of side reaction products. An alternative purification approach based on hydrophilic interaction liquid chromatography (HILIC) allowed the formation of glutaric acid conjugates to be avoided, and a design of experiment (DoE) approach led to optimal glycan loading. Once its suitability was proven, the developed conjugation strategy was applied to the chemical glycosylation of two recombinant antigens, native Ag85B and its variant Ag85B-dm, that are candidate carriers for the development of a novel antitubercular vaccine. Pure glycoconjugates (≥99.5%) were obtained. Altogether, the results suggest that, with an adequate protocol, conjugation via disuccinimidyl linkers can be a valuable approach to produce high sugar-loaded and well-defined glycovaccines.
文献报道,通过二琥珀酰亚胺基同双功能连接子进行共轭是合成糖缀合物疫苗的一种便捷方法。然而,二琥珀酰亚胺基连接子的高水解倾向阻碍了它们的广泛纯化,这不可避免地导致副反应和不纯的糖缀合物。在本文中,利用戊二酸二琥珀酰亚胺酯(DSG)对3-氨丙基糖类进行共轭反应来合成糖缀合物。首先考虑使用一种模型蛋白核糖核酸酶A(RNase A)来建立与单至三甘露糖糖类的共轭策略。通过对合成的糖缀合物进行详细表征,对纯化方案和共轭条件进行了修订和优化,以实现两个目标:确保高糖负载量并避免副反应产物的存在。基于亲水相互作用液相色谱(HILIC)的另一种纯化方法可以避免戊二酸共轭物的形成,实验设计(DoE)方法则实现了最佳的聚糖负载量。一旦证明其适用性,就将开发的共轭策略应用于两种重组抗原(天然Ag85B及其变体Ag85B-dm)的化学糖基化,这两种抗原是开发新型抗结核疫苗的候选载体。获得了纯度≥99.5%的糖缀合物。总之,结果表明,通过适当的方案,使用二琥珀酰亚胺基连接子进行共轭可以成为生产高糖负载量且明确的糖疫苗的有价值方法。